Crossmark

Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study

Published Online: 2026-04-10

Authors

Ishikawa, Hitoshi

Oka, Koji

Inoue, Hiroshi
Funding

Funding for this research was provided by:

Santen
License Information

Text and Data Mining valid from 2026-04-10

Version of Record valid from 2026-04-10
More Information

Article History

Received: 12 September 2025

Accepted: 4 February 2026

First Online: 10 April 2026

Declarations

:

: H. Ishikawa, Consultant (Chugai, Alexion, Santen); K. Oka, Employee (Santen); H. Inoue, Employee (Santen).

Document is current